Expertise in
6
conditions

Bernard J. Escudier

Centro De Invetigación Clínica Bradford Hill
Santiago, RM, CL 
Expertise in
6
conditions
Centro De Invetigación Clínica Bradford Hill
Santiago, RM, CL 

Overview

Bernard Escudier practices practicing medicine in Santiago, Chile.

Mr. Escudier is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Diarrhea, Nephrectomy, and Thrombectomy.

He is actively involved in clinical research, co-authoring 333 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Centro de Invetigación Clínica Bradford Hill
Santiago, RM, Chile
Other Locations
Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: March 31, 2026
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
Multicenter Phase II Study of Axitinib in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Multicenter Phase II Study of Axitinib in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Enrollment Status: Completed
Publish Date: September 06, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma
A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: December 06, 2021
Intervention Type: Drug
Study Drugs: Tivozanib, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
View 4 Less Clinical Trials

333 Total Publications

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2026

Frequently Asked Questions about Bernard J. Escudier

Is Bernard J. Escudier a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Bernard J. Escudier is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bernard J. Escudier participate in research or clinical trials?

Yes. Bernard J. Escudier has published 333 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Bernard J. Escudier's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Escudier's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile